Literature DB >> 12478413

Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.

Nicholas R Banner1, Olivier J David, Neil Leaver, Julie Davis, Jane Breen, Atholl Johnston, Magdi H Yacoub.   

Abstract

Neoral cyclosporine has better absorption characteristics than the original Sandimmun formulation. This has allowed Neoral to be administered orally in circumstances where Sandimmun had been ineffective, including the postoperative phase of liver transplantation. Sampling strategies, such as the measurement of drug concentration 2 h after oral administration, have been used in a variety of settings to estimate systemic exposure to Neoral (measured as the area under the blood concentration curve (AUC) of the drug) in blood. We conducted a pilot study to determine whether Neoral could be administered orally immediately after heart transplantation and to determine which pharmacokinetic parameters reflect systemic drug exposure in this setting. Eight male patients (mean age 50 years) undergoing a first heart transplant were studied. Neoral was administered orally before surgery and at 12-h intervals via a nasogastric tube after surgery. Twelve-hour pharmacokinetic profiles were obtained on postoperative days 1, 3 and 5. Cyclosporine concentrations were measured with the Dade Behring Emit assay, which is specific for the parent drug. Drug concentrations were dose-normalised and drug exposure was measured by the AUC. Drug exposure following administration (AUC(0-12)) was low on day 1 but increased by 99% between postoperative day 1 and day 5 ( P<0.05), indicating more complete absorption of cyclosporine; exposure in the first 4 h post-dose (AUC(0-4)) increased by 126% ( P<0.01), reflecting more rapid cyclosporine absorption, and the maximum blood concentration observed increased by 137% ( P<0.05) during the same period. The correlation between the cyclosporine trough concentration and AUC(0-12) was low on all days. Due to the changing pattern of cyclosporine absorption, concentration measurements at a single time point could not accurately predict 12-h exposure to the drug on all study days. However, the drug concentration at 2 h post-dose had a high correlation with drug exposure during the first 4 h (correlation of C(2) to AUC(0-4): r(2)>0.93 on all days). Absorption of Neoral was low immediately after heart transplantation but improved substantially during the first 5 days after surgery. No single timed measurement of drug concentration reflected cyclosporine exposure; however, the 2-h concentration did provide an accurate measure of the early phase of drug absorption (AUC(0-4)). Oral administration of Neoral may result in inadequate immunosuppression immediately after heart transplantation unless it is supplemented either by intravenous cyclosporine or by the use of an induction agent.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12478413     DOI: 10.1007/s00147-002-0491-0

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  3 in total

1.  Optimal sampling time-point for cyclosporin A concentration monitoring in heart transplant recipients.

Authors:  Yixin Jia; Xu Meng; Yan Li; Chunlei Xu; Wen Zeng; Yuqing Jiao; Wei Han
Journal:  Exp Ther Med       Date:  2018-09-10       Impact factor: 2.447

Review 2.  Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients.

Authors:  Federico Pea; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

3.  Early non-steady-state population pharmacokinetics of oral cyclosporine in renal transplant recipients.

Authors:  Hyunjeong Baek; Seunghoon Han; Dong-Seok Yim; Sung Joo Kim; Soo-Youn Lee; Hye Ryoun Jang; Jung Eun Lee; Dae Joong Kim; Yoon-Goo Kim; Ha Young Oh; Wooseong Huh
Journal:  Drug Des Devel Ther       Date:  2014-11-07       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.